(The product is intended for scientific research and development purposes only. Not for human consumption.)


Retatrutide is an innovative investigational peptide developed by Eli Lilly that functions as a triple agonist of the GLP-1, GIP, and glucagon receptors—also referred to as a GGG triagonist. This combined receptor activation results in a synergistic effect on body weight reduction through increased energy expenditure, decreased food intake, delayed gastric emptying, and stimulation of lipolysis. Phase 2 clinical trials have demonstrated that retatrutide can reduce body weight by up to 24.2% over a 48-week period, while also improving cardiometabolic parameters such as blood pressure, lipid profile, and insulin sensitivity. Promising outcomes observed in both preclinical and clinical populations position retatrutide as one of the most promising candidates for the treatment of obesity and metabolic diseases, although further research remains necessary.

(The product is intended for scientific research and development purposes only. Not for human consumption.)